ArticleFrontiers in pharmacology2024

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.

Gengwei Huo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.